Remove company abcellera
article thumbnail

Abdera raises funds to advance radiopharmaceuticals to treat cancer

Pharmaceutical Technology

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The Series A financing round was led by Amplitude Ventures and Versant Ventures, with Northview Ventures, AbCellera and adMare BioInnovations as participants.

article thumbnail

Leading innovators in IgG gene expressing animal models for the pharmaceutical industry

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. In terms of application diversity, Vivoryon Therapeutics is the top company, followed by MannKind, and Onxeo SA.

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leading innovators in transgenic murine models for the pharmaceutical industry

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

Leads 52
article thumbnail

Artificial Intelligence for better antibody drugs: ready for prime time?

pharmaphorum

As a result, 2022 saw a breakthrough when the first ever computationally designed antibody created by Israel-based Biolojic design entered clinical trial , further fuelling the interest of biopharma companies. Although the space is in a nascent stage, several AI companies have made meaningful progress over the last few years.

article thumbnail

Confo Therapeutics and AbCellera partner on GPCR-targeting antibodies

Pharmaceutical Technology

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. In March 2023, Confo Therapeutics and Eli Lilly and Company entered a global licence agreement for the former’s clinical-stage peripheral pain candidate, CFTX-1554.